Liraglutide
Liraglutide
The first GLP-1 receptor agonist approved for both type 2 diabetes (Victoza) and weight management (Saxenda). Requires daily injection.
Typical Cost
$900-1200/month (brand)
Status
Research
Peptide Profile
Liraglutide
Mechanism of Action
Activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite. Same mechanism as other GLP-1s but with shorter duration requiring daily dosing.
Common Dosages
subcutaneous
0.6-3.0mg
Daily · Ongoing
Benefits
Weight loss 8-10%
Improved glycemic control
Cardiovascular protection
Reduced appetite
Proven long-term safety
Side Effects
Nausea
Vomiting
Diarrhea
Constipation
Injection site reactions
Daily injection burden
Key Research
SCALE trial - Liraglutide for obesity
Average 8% weight loss at 56 weeks with 3.0mg dose
LEADER trial - Cardiovascular outcomes
Reduced cardiovascular events in type 2 diabetes patients
Regulatory Status
FDA-approved (Victoza for diabetes, Saxenda for weight). Available by prescription.
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠MEN2 syndrome
- ⚠Pregnancy/breastfeeding
GLP-1 users on liraglutide benefit from SeraVia Gut+ Balance for nausea management and Muscle+ Protect for lean mass preservation.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.